Page last updated: 2024-12-05

pindobind

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID4827
CHEMBL ID156628
MeSH IDM0224998

Synonyms (14)

Synonym
106469-52-7
PDSP1_001698
PDSP2_001681
pindobind
L003444
CHEMBL156628 ,
2-bromo-n-[4-[2-[[2-hydroxy-3-(1h-indol-4-yloxy)propyl]amino]propan-2-yl]-1-methylcyclohexyl]acetamide
n(1)-(bromoacetyl)-n(8)-(3-(4-indolyloxy)-2-hydroxypropyl)-(z)-1,8-diamino-4-menthane
acetamide, 2-bromo-n-(4-(1-((2-hydroxy-3-(1h-indol-4-yloxy)propyl)amino)-1-methylethyl)-1-methylcyclohexyl)-
pindobind 5-hydroxytryptamine(1a)
2-bromo-n-(4-(1-((2-hydroxy-3-(1h-indol-4-yloxy)propyl)amino)-1-methylethyl)-1-methylcyclohexyl)acetamide
bdbm50226718
Q7195029
DTXSID80910012

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Pindobind-treated monocytes suppressed NKCA, whereas pindobind treatment of PBL did not affect NKCA."( Monocyte 5-HT1A receptors mediate pindobind suppression of natural killer cell activity: modulation by catalase.
Frank, JL; Frank, MG; Hendricks, SE; Johnson, DR, 2001
)
1.31

Dosage Studied

ExcerptRelevanceReference
" For serotonin-induced phospholipase C stimulation, reductions in receptor number result in dose-response curves that shift downward and rightward, reflecting both a decreasing maximal effect as well as an increasing ED50."( The human 5-hydroxytryptamine 1A receptor differentially modulates phospholipase C and adenylyl cyclase activities.
Beliveau, M; Fargin, A; Fenrick, R; Pou, C, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-2 adrenergic receptorRattus norvegicus (Norway rat)Ki0.01350.00050.35461.6000AID41632; AID41633
Beta-1 adrenergic receptorRattus norvegicus (Norway rat)Ki0.01350.00000.667310.0000AID41632; AID41633
Beta-3 adrenergic receptorRattus norvegicus (Norway rat)Ki0.01350.00050.33671.6000AID41632; AID41633
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-2 adrenergic receptorRattus norvegicus (Norway rat)Kd0.00170.00140.06510.3910AID41614; AID41617
Beta-1 adrenergic receptorRattus norvegicus (Norway rat)Kd0.00170.00140.06010.3910AID41614; AID41617
Beta-3 adrenergic receptorRattus norvegicus (Norway rat)Kd0.00170.00140.06510.3910AID41614; AID41617
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID41776Percent potency for irreversible blockade of the [3H]dihydroalprenolol binding to beta adrenergic receptor of rat heart reticulocytes pretreated with alkylating beta blockers1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Affinity labels for beta-adrenoceptors: preparation and properties of alkylating beta-blockers derived from indole.
AID41877Percent potency for irreversible blockade of the [3H]dihydroalprenolol binding to beta adrenergic receptor of rat lung reticulocyte pretreated with alkylating beta-blockers1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Affinity labels for beta-adrenoceptors: preparation and properties of alkylating beta-blockers derived from indole.
AID41632Binding affinity against beta adrenergic receptor from rat heart tissues was determined1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Affinity labels for beta-adrenoceptors: preparation and properties of alkylating beta-blockers derived from indole.
AID41614Binding affinity against the [3H]dihydroalprenolol binding sites on beta adrenergic receptor of rat heart reticulocytes pretreated with alkylating beta-blockers1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Affinity labels for beta-adrenoceptors: preparation and properties of alkylating beta-blockers derived from indole.
AID41467Concentration of binding sites of protein for [3H]dihydroalprenolol binding to beta adrenergic receptor of rat lung reticulocytes was determined1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Affinity labels for beta-adrenoceptors: preparation and properties of alkylating beta-blockers derived from indole.
AID41617Binding affinity against the [3H]dihydroalprenolol binding to beta adrenergic receptor of rat lung reticulocytes pretreated with alkylating beta-blockers1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Affinity labels for beta-adrenoceptors: preparation and properties of alkylating beta-blockers derived from indole.
AID41633Binding affinity against beta adrenergic receptor from rat lung tissues was determined1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Affinity labels for beta-adrenoceptors: preparation and properties of alkylating beta-blockers derived from indole.
AID41463Concentration of binding sites of protein for [3H]dihydroalprenolol binding to beta adrenergic receptor of rat heart reticulocytes was determined1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Affinity labels for beta-adrenoceptors: preparation and properties of alkylating beta-blockers derived from indole.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (5.88)18.7374
1990's11 (64.71)18.2507
2000's5 (29.41)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]